Annette Byrne
#178,506
Most Influential Person Now
Irish physiologist and researcher
Annette Byrne's AcademicInfluence.com Rankings
Annette Byrnebiology Degrees
Biology
#15533
World Rank
#19537
Historical Rank
Physiology
#530
World Rank
#789
Historical Rank
Download Badge
Biology
Annette Byrne's Degrees
- PhD Physiology National University of Ireland
- Bachelors Biomedical Science National University of Ireland
Why Is Annette Byrne Influential?
(Suggest an Edit or Addition)According to Wikipedia, Annette Therese Byrne is an Irish physiologist, Professor and Head of the Royal College of Surgeons in Ireland Precision Cancer Medicine group. Her research considers metastatic colorectal cancer and glioblastoma.
Annette Byrne's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Patient-derived xenograft models: an emerging platform for translational cancer research. (2014) (1214)
- Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy (2009) (949)
- Interrogating open issues in cancer precision medicine with patient-derived xenografts (2017) (462)
- Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. (2003) (320)
- Supramolecular photonic therapeutic agents. (2005) (279)
- Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. (2002) (252)
- Bioluminescent imaging: a critical tool in pre‐clinical oncology research (2010) (159)
- An Intact Canonical NF-κB Pathway Is Required for Inflammatory Gene Expression in Response to Hypoxia (2011) (139)
- The Hydroxylase Inhibitor Dimethyloxallyl Glycine Attenuates Endotoxic Shock Via Alternative Activation of Macrophages and IL-10 Production by B1 Cells (2011) (87)
- Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2019) (81)
- PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. (2017) (79)
- Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment (2009) (78)
- The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. (2011) (66)
- AKT1E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection (2016) (58)
- Glioma progression is shaped by genetic evolution and microenvironment interactions (2022) (56)
- Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. (2010) (51)
- The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate. (2013) (49)
- Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy (2018) (49)
- Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells (2011) (44)
- Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach (2011) (41)
- Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors. (2014) (38)
- Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer (2017) (38)
- Therapeutic Targeting of the Colorectal Tumor Stroma. (2020) (37)
- Mechanism of cell death mediated by a BF2‐chelated tetraaryl‐azadipyrromethene photodynamic therapeutic: Dissection of the apoptotic pathway in vitro and in vivo (2012) (37)
- Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation (2014) (35)
- Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models (2014) (30)
- New hints towards a precision medicine strategy for IDH wild-type Glioblastoma. (2020) (26)
- Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A (2019) (26)
- Erratum: Interrogating open issues in cancer medicine with patient-derived xenografts (2017) (26)
- The hydroxylase inhibitor DMOG attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B-1 cells (2011) (26)
- Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. (2018) (25)
- A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate (2017) (23)
- Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability. (2010) (23)
- In Vivo Bioluminescence Imaging Validation of a Human Biopsy–Derived Orthotopic Mouse Model of Glioblastoma Multiforme (2013) (23)
- The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy? (2016) (21)
- Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary. (2013) (19)
- Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant (2015) (17)
- Precision therapy in RAS mutant colorectal cancer. (2020) (16)
- Validation of an imageable surgical resection animal model of Glioblastoma (GBM) (2014) (15)
- Colorectal tumour simulation using agent based modelling and high performance computing (2017) (13)
- Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative (2016) (13)
- Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers (2016) (13)
- Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (12)
- Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancer (2018) (11)
- Comparison of performance in a four year graduate entry medical programme and a traditional five/six year programme (2014) (10)
- Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer. (2016) (10)
- Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma (2019) (9)
- Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach (2017) (9)
- When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All? (2019) (9)
- Comparison of anthropometric-based equations for estimation of body fat percentage in a normal-weight and overweight female cohort: validation via air-displacement plethysmography (2014) (7)
- Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial (2019) (7)
- RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells (2019) (6)
- Anti-angiogenic drug scheduling optimisation with application to colorectal cancer (2018) (5)
- Aryl hydrocarbon receptor nuclear translocator-like ( ARNTL / BMAL 1 ) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A (2019) (5)
- Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate (2019) (4)
- Modelling tumour cell proliferation from vascular structure using tissue decomposition into avascular elements. (2016) (4)
- Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer (2020) (4)
- Angiogenesis and Invasion (2010) (3)
- Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies (2020) (3)
- Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer (2021) (3)
- Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications (2015) (3)
- 79 The RON (MST1R)/MSP pathway is a potential therapeutic target in malignant pleural mesothelioma (2014) (3)
- Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models (2020) (3)
- Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents (2019) (3)
- Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (2)
- Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials. (2013) (2)
- Targeting the 19 S proteasomal subunit , Rpt 4 , for the treatment of colon cancer (2019) (2)
- Refining Glioblastoma Surgery through the Use of Intra-Operative Fluorescence Imaging Agents (2022) (2)
- TAMI-51. IDENTIFYING NEW TUMOR MICROENVIRONMENT (TME) CONTEXTS OF VULNERABILITY IN GLIOBLASTOMA (2020) (1)
- But it came from a Food Pantry: Product Stigma and Quality Perceptions of Food Pantry Offerings (2021) (1)
- New cell-based assay for comparison of caspase 3/7 activity in normal versus tumor cell populations (2006) (1)
- Copy number alterations as predictive biomarkers for response to bevacizumab in metastatic colorectal cancer (2016) (1)
- A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso. (2018) (1)
- Abstract 5634: Increased co-amplification of HER2 and STARD3 in a cell line model of acquired lapatinib resistance. (2013) (1)
- Identification of a novel predictive genomic biomarker for response to combination bevacizumab in metastatic colorectal cancer (mCRC). (2017) (1)
- SATB2 loss and the immune milieu of colorectal cancer (CRC). (2018) (1)
- Cardiac Metabolic Pathway Remodelling in Response to Sunitinib Malate: Potential Role for Positron Emission Tomography in the Cardio-Oncology Setting (2016) (0)
- Abstract 4529: Tailoring approaches for global epigenome analysis from archival formalin-fixed paraffin-embedded tissue samples (2016) (0)
- Anti-angiogenic drug scheduling optimisation with application to colorectal cancer (2018) (0)
- Abstract 3269: Recapitulating the BETH adjuvant breast cancer trial (NCT00625898) using clinically accurate orthotopic surgical resection models (2016) (0)
- Emerging role of novel molecular subtypes to predict colorectal cancer clinical outcome (2018) (0)
- 932 Targeting the 19S Proteasomal Subunit, Rpt4, in Colon Cancer Cells Induces Cell Death and Reduces Cellular Proliferation In Vitro and In Vivo (2013) (0)
- Abstract 1254: Mechanistic interrogation of pre-treatment low dose aspirin effects in HER 2 positive breast cancer (2017) (0)
- Correlation of BMAL1 expression in colorectal cancer with resistance to anti-VEGFA therapy with bevacizumab. (2018) (0)
- 56: Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma (2017) (0)
- P3.03-021 When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?: Topic: Mesothelioma Transitional (2017) (0)
- Abstract 5093: Pre-clinical assessment of a novel anti-invasion nanoparticle therapeutic in combination with bevacizumab for the treatment of glioblastoma (2015) (0)
- MODL-27. PRECLINICAL INTERROGATION OF IMMUNOTHERAPY TREATMENT STRATEGIES IN GLIOBLASTOMA (GBM) USING A CLINICALLY RELEVANT DISEASE MODEL (2022) (0)
- AI-010. ACTIVATION OF THE PROTOTYPICAL SFK C-Src PROMOTES ANGIOGENESIS OF HUMAN GLIOBLASTOMA (2013) (0)
- P04.08 GLIOTRAIN: Exploiting Glioblastoma intractability to address European research training needs in translational brain tumour research, cancer systems medicine and integrative multi-omics (2018) (0)
- TMOD-12. ESTABLISHING A CLINICALLY RELEVANT MODEL OF MESENCHYMAL GLIOBLASTOMA (GBM) TO STUDY RESPONSE TO STANDARD OF CARE TREATMENT AND IMMUNE CHECKPOINT INHIBITION (ICI). (2020) (0)
- Imaging Targeted Therapy Response and Resistance in Glioblastoma (2016) (0)
- Abstract 2012: Interrogating thein vivoanti-metastatic action of tinzaparin and simvastatin in an orthotopic surgical resection mouse model of triple negative breast cancer (2019) (0)
- Abstract 1118: Absence of mouse-specific tumor evolution in patient-derived cancer xenografts (2020) (0)
- Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents (2019) (0)
- AKT1E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection (2016) (0)
- MODL-24. ESTABLISHING A CLINICALLY RELEVANT CT AND ASSOCIATED RADIOMICS PIPELINE FOR INTRACRANIAL RODENT TUMOUR MODELS (2022) (0)
- Author Correction: Anti-angiogenic drug scheduling optimisation with application to colorectal cancer (2018) (0)
- Abstract 1828: Analysis of putative serum biomarker candidates for cardiotoxicity prediction in a cohort of early stage breast cancer patients treated with docetaxel, cyclophosphamide, and bevacizumab (2016) (0)
- Abstract 2579: Loss of chromosome 18q11.2-18q12.1 is predictive for progression-free survival in metastatic colorectal cancer patients treated with bevacizumab (2018) (0)
- 1 Mechanistic interrogation of combination Bevacizumab / dual PI 3 K / mTOR inhibitor 1 response in Glioblastoma implementing novel MR and PET imaging biomarkers . 2 3 (2016) (0)
- A potent nonporphyrin class of photodynamic therapeutic agent: Preclinical and mechanistic studies (2007) (0)
- Implementing subtype‐specific pre‐clinical models of breast cancer to study pre‐treatment aspirin effects (2022) (0)
- 86 When RON MET TAM: potential interventions for mesothelioma therapy (2016) (0)
- Abstract LB-40: Guanine nucleotide exchange factors Dock7 and Ect2 mediate HGF/c-MET-induced glioblastoma cell invasion. (2013) (0)
- ANGI-08. TARGETING THE RhoGEF BETA-PIX TO ENHANCE THE ACTIVITY OF BEVACIZUMAB IN GLIOBLASTOMA: A NANOPARTICLE MEDIATED GENE SILENCING APPROACH (2018) (0)
- Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy (2018) (0)
- 162PTargeting the RON/MET/TAM signalling network in mesothelioma (2017) (0)
- Abstract 5033: The role of the epigenetic regulator SATB2 in colon cancer progression (2019) (0)
- Impact of Aspirin on factors associated with breast cancer lymph node metastasis (2016) (0)
- RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells (2019) (0)
- Abstract LB-515: Guanine nucleotide exchange factor Dock7 expression is increased in human glioblastoma and mediates tumor cell invasion. (2012) (0)
- Abstract 3010: Proteomic analysis of off-target toxicities following treatment with the tyrosine kinase inhibitor sunitinib (2016) (0)
- EXTH-30. EXPANDING THE UTILITY OF PRE-CLINICAL CONTRAST ENHANCED CT (CE-CT) FOR TUMOR DETECTION IN ORTHOTOPIC GBM MODELS USING RADIOMICS (2020) (0)
- INDEPENDENT FUNCTIONAL ASSESSMENT: A FUTURE DEVELOPMENT IN OCCUPATIONAL HEALTH (2011) (0)
- P1.09-007 Targeting MET/TAM Receptors in Mesothelioma: Are Multi-TKIs Superior to Specific TKI? (2017) (0)
- Biomarker-driven studies in metastatic colorectal cancer (mCRC): Challenges and opportunities (2014) (0)
- Abstract 985: The EurOPDX EDIReX project: Towards a European research infrastructure on patient-derived cancer models (2018) (0)
- ArticleImplementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL- (2020) (0)
- BF2-Azadipyrromethene Fluorophores for Intraoperative Vital Structure Identification (2023) (0)
- BMAL1 Links Bevacizumab Resistance in Colorectal Cancer to Circadian Rhythm and Heme Receptor REVERBA (2019) (0)
- Neuromedin U: A Candidate Biomarker and Therapeutic Targetto Predict and Overcome Resistance to HER-Tyrosine (2015) (0)
- Identification, validation and biological characterization of novel Glioblastoma Tumour Microenvironment subtypes: Implications for precision immunotherapy. (2022) (0)
- Abstract 2096: Mechanistic insights into the pathogenesis of anti-DLL4-related hepatic sinusoidal dilatation (2016) (0)
- Abstract 1685: The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts (2020) (0)
- Abstract 5584: Analysis of cell free DNA to predict outcome to Bevacizumab combination therapy in metastatic colorectal cancer patients (2023) (0)
- Author Correction: Anti-angiogenic drug scheduling optimisation with application to colorectal cancer (2018) (0)
- Chromosome 18q11.2 loss as a predictive marker for response to bevacizumab in metastatic colorectal cancer (2016) (0)
This paper list is powered by the following services:
Other Resources About Annette Byrne
What Schools Are Affiliated With Annette Byrne?
Annette Byrne is affiliated with the following schools:
